Chronic Kidney Disease Clinical Trial
Official title:
Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease
Papilledema is defined as swelling of the optic nerves often due to increased intracranial
pressure. When present, it often indicates life-threatening lesions of the brain such as
tumors, abscesses, meningitis, encephalitis, venous sinus obstruction or intracranial
hemorrhage. A similar clinical picture can also be caused by other conditions such as
malignant hypertension, diabetic papillopathy and uremia. When the intracranial pressure is
elevated in the absence of any known cause then it is called Idiopathic Intracranial
Hypertension (IIH). Untreated papilledema can cause progressive optic nerve damage and
blindness.
Patients with chronic kidney disease have a number of co-morbidities and thus are at an
increased risk for developing papilledema. Although clinicians have observed that patients
with kidney diseases have increased incidence of papilledema (unpublished data by Corbett et
al), there have been no studies on this subject to date. We believe that a higher incidence
of papilledema is found in patients with kidney diseases and this study could provide
evidence to suggest routine ophthalmic screening in this patient group.
Hypothesis: The prevalence of optic disc swelling is increased in patients with chronic
kidney disease.
Purpose: To establish the prevalence of disc edema in patients with chronic kidney disease.
The craniospinal cavity is enclosed by a rigid, non-compressible bone and thus has a constant
volume. It is filled with soft tissue (brain, spinal cord and connective tissue),
cerebrospinal fluid (CSF) and circulating blood. Intracranial pressure (ICP) is the pressure
of the fluid that bathes the brain and the spinal cord. The ICP is regulated by a fine
balance between the production and absorption of CSF. Any disturbance in the volumes of the
contents of the rigid craniospinal cavity will cause an alteration of the ICP. Intracranial
pressure can be elevated from a number of disease processes such as space occupying lesions,
abnormalities of the production and absorption of the CSF and abnormalities of the
circulation such as venous obstruction.
Raised ICP will symptomatically manifest as headache, vomiting, tinnitus and diplopia in
addition to neurologic symptoms related to the lesion location and type. The increased ICP
can be transmitted to the optic nerves causing papilledema, defined as swelling of the optic
nerve head (papilla) secondary to raised ICP. Swelling of the optic nerves in the absence of
raised ICP is termed disc edema (Parsons JH, Miller NR). Causes of disc edema are extensive
and include ischemic optic neuropathy, malignant hypertension, diabetic papillopathy, uremia,
intracranial hypotension (CSF leak).
Papilledema is considered a medical emergency and is investigated by means of neuroimaging
(to evaluate intracranial lesions) and lumbar puncture (to evaluate the opening pressure and
CSF contents). A diagnosis of Idiopathic Intracranial Hypertension (IIH) is made when there
is elevated ICP in the absence of clinical, laboratory or radiological evidence of any known
cause of raised ICP.
The most feared complication of untreated papilledema is progressive optic nerve atrophy
resulting in vision loss. Early recognition, investigation and treatment of papilledema and
its causes can prevent blindness.
Patients with chronic kidney diseases have a number of risk factors which predispose them to
the development of disc edema. Medical comorbidities such as hypertension and diabetes
mellitus increase their risk for optic nerve head diseases such as ischemic optic neuropathy
and diabetic papillopathy. Malignant hypertension, uremia and dialysis dysequilibrium
syndrome also are known to cause papilledema.
There are no studies in the English literature to date, on disc edema in patients with kidney
diseases. However, neuroophthalmologists have clinically observed that patients with chronic
kidney diseases appear to have an increased incidence of optic nerve swelling (Corbett JJ,
unpublished data). A study looking at optic nerve edema in this group of patients is overdue
and may determine additional guidelines in the management of patients with chronic kidney
diseases.
The patients enrolled in the study will undergo an optic nerve head examination by
ophthalmoscopy to identify patients with disc edema. If disc edema is detected on the
screening examination, the patients will be referred to the Neuroophthalmology service for
evaluation and investigations to determine the further management. The results of the
neuroophthalmologic workup for patients with disc edema will be reviewed to ascertain the
etiology of disc edema.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |